Table 1 Demographic and baseline characteristics
Characteristic | Healthy volunteers | Patients with T2DM | |||||
|---|---|---|---|---|---|---|---|
Placebo | Volixibat | Placebo | Volixibat | ||||
(n = 12) | 0.5 mg (n = 10) | 1 mg (n = 9) | 5 mg (n = 9) | 10 mg (n = 9) | (n = 3) | 10 mg (n = 8) | |
Age, years | 38.9 ± 15.58 (20–62) | 28.2 ± 11.65 (19–54) | 28.9 ± 10.86 (19–45) | 30.2 ± 12.46 (19–54) | 59.6 ± 4.72 (55–65) | 67.7 ± 2.08 (66–70) | 65.5 ± 3.38 (61–70) |
BMI, kg/m2 | 23.82 ± 1.816 (21.6–27.4) | 23.74 ± 3.301 (20.1–28.7) | 24.10 ± 2.841 (20.2–28.9) | 23.12 ± 3.423 (19.0–29.1) | 22.79 ± 2.958 (18.7–28.8) | 29.77 ± 1.914 (28.0–31.8) | 29.49 ± 3.512 (24.4–34.8) |
Female, n (%) | 7 (58.3) | 2 (20.0) | 4 (44.4) | 2 (22.2) | 5 (55.6) | 0 | 0 |
Race, n (%) | |||||||
 Caucasian | 11 (91.7) | 9 (90.0) | 7 (77.8) | 7 (77.8) | 9 (100.0) | 3 (100.0) | 7 (87.5) |
 Other | 1 (8.3) | 1 (10.0) | 2 (22.2) | 2 (22.2) | 0 | 0 | 1 (12.5) |